Summary
0R2B Chart
Danaher: Biotech Momentum, Cost Cuts And Valuation Re-Rating Should Drive Upside
Danaher is positioned for a revenue rebound, led by strong bioprocessing demand and resilient recurring sales, despite short-term headwinds in Life Sciences and China. Margin outlook is stable, supported by a $150M cost-cutting program and proactive tariff mitigation. Shares trade below their 5-year average P/E, offering compelling upside, as growth recovers and margin initiatives take hold.
CVS vs. DHR: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical Services sector have probably already heard of CVS Health (CVS) and Danaher (DHR). But which of these two stocks offers value investors a better bang for their buck right now?
Danaher Appoints Martin Stumpe as Chief Technology and AI Officer
WASHINGTON , June 27, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a leading global life sciences and diagnostics innovator, today announced that Martin Stumpe will be appointed Chief Technology and AI Officer, effective October 1, 2025. He will report directly to Rainer Blair, President and Chief Executive Officer.
Danaher Corporation Dividends
 0R2B 3 months ago | Other | $0.32 Per Share |
| 0R2B 6 months ago | Other | $0.27 Per Share |
| 0R2B 9 months ago | Other | $0.27 Per Share |
| 0R2B 28 Jun 2024 | Other | $0.27 Per Share |
| 0R2B 27 Mar 2024 | Other | $0.27 Per Share |
Danaher Corporation Earnings
| 22 Jul 2025 (In 2 weeks) Date | | 1.64 Cons. EPS | - EPS |
| 21 Jul 2025 (In 2 weeks) Date | | - Cons. EPS | - EPS |
| 21 Apr 2025 Date | | - Cons. EPS | - EPS |
| 28 Jan 2025 Date | | - Cons. EPS | - EPS |
| 22 Oct 2024 Date | | - Cons. EPS | 1.12 EPS |
| 0R2B 3 months ago | Other | $0.32 Per Share |
| 0R2B 6 months ago | Other | $0.27 Per Share |
| 0R2B 9 months ago | Other | $0.27 Per Share |
| 0R2B 28 Jun 2024 | Other | $0.27 Per Share |
| 0R2B 27 Mar 2024 | Other | $0.27 Per Share |
| 22 Jul 2025 (In 2 weeks) Date | | 1.64 Cons. EPS | - EPS |
| 21 Jul 2025 (In 2 weeks) Date | | - Cons. EPS | - EPS |
| 21 Apr 2025 Date | | - Cons. EPS | - EPS |
| 28 Jan 2025 Date | | - Cons. EPS | - EPS |
| 22 Oct 2024 Date | | - Cons. EPS | 1.12 EPS |
Danaher Corporation (0R2B) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Danaher Corporation ever had a stock split?
Danaher Corporation Profile
| Medical - Diagnostics & Research Industry | Healthcare Sector | Rainer M. Blair CEO | LSE Exchange | US2358511028 ISIN |
| US Country | 61,000 Employees | 28 Mar 2025 Last Dividend | 2 Oct 2023 Last Split | 5 Jan 1979 IPO Date |
Overview
Danaher Corporation is a global powerhouse in the design, manufacturing, and marketing of a vast array of professional, medical, industrial, and commercial products and services. With its inception in 1969 and a significant rebranding in 1984, where it transitioned from Diversified Mortgage Investors, Inc. to Danaher Corporation, the company has established a formidable presence in various sectors. Headquartered in Washington, D.C., Danaher stands out through its commitment to innovation, excellence, and enhancing the quality of life worldwide.
Products and Services
- Biotechnology: Danaher's biotechnology segment is a provider of bioprocess technologies, consumables, and services enhancing the development and manufacture of therapeutics. This includes cell line and cell culture media development, chromatography resins, filtration technologies, aseptic fill-finish solutions, single-use hardware, and comprehensive services aimed at setting up full manufacturing suites.
- Life Sciences: This segment delivers a wide range of products including mass spectrometers, flow cytometry, genomics solutions, lab automation instruments, centrifugation, liquid handling automation instruments, antibodies and reagents, particle counting and characterization tools, microscopes, and protein consumables. Among the notable brands under the Life Sciences segment are ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX, each providing specialized products for genomic medicines and industrial filtration.
- Diagnostics: Danaher’s diagnostics sector offers a comprehensive range of chemistry, immunoassay, microbiology, automation systems, molecular diagnostics, acute care, and pathology diagnostics products. Aimed at hospitals, physicians' offices, reference laboratories, and other critical care settings, this segment ensures the delivery of clinical instruments, reagents, consumables, software, and dedicated services to support critical diagnostics.
Contact Information
